Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine for recovery from moderate rocuronium-induced neuromuscular blockade in anesthetized healthy volunteers
2013-002078-30Phase 4Completed
- Sponsor
- OLV Hospital
- Start
- Jul 2013
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Sugammadex, neostigmine and rocuronium (2 arms), sponsored by OLV Hospital. Primary endpoints: Diaphragmatic electromyographic activity and Recovery of diaphragmatic function at return of spontaneous breathing. Started Jul 2013; status: completed.
02
Drugs
Sugammadexneostigminerocuronium
Beyond the preview
Go deeper on 2013-002078-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002078-30.